[Clinical, pathology-associated and molecular biomarkers of hidradenitis suppurativa/acne inversa].

von Laffert, M; Hunger, R E; Navarini, A A; Zouboulis, C C (2021). [Clinical, pathology-associated and molecular biomarkers of hidradenitis suppurativa/acne inversa]. Der Hautarzt, 72(8), pp. 666-675. Springer 10.1007/s00105-021-04848-8

Text VonLaffert2021_Article_KlinischePathologischeUndMolek.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (2MB) | Request a copy

Hidradenitis suppurativa/acne inversa is a scarring disease of the intertrigines that is now intensively researched. Improved pathogenetic understanding has led to the introduction of tumor necrosis factor alpha (TNF‑α) inhibition, which represents a major advance over traditional broad immunosuppression and antibiotic administration. In addition, a wide range of newer and promising treatments is or is about to be clinically evaluated. These include various specific antibodies against cytokines and the complement system and small molecules. Successful use of the individual drugs depends on the stratification of suitable patient groups with the help of clinically relevant biomarkers. While molecular investigations have shown a number of possible biomarkers and/or therapeutic target molecules, the detection of robust predictive biomarkers is still in its initial phase. In summary, the therapeutic options for hidradenitis suppurativa/acne inversa are improving through the introduction of new drugs, possibly in combination with surgical interventions, whereby the possibilities for predictive therapeutic decisions through the discovery of biomarkers would revolutionize the chances of therapeutic success.

Interest & Impact

Downloads

2 since deposited on 01 Feb 2022
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item